Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22102488 | 0.90 | HDAC1 (0.40) | GRM1KCNQ3KCNQ2KCNQ5MAOB | |
| SCHEMBL26003352 | 0.82 | KDM4E (0.42) | GRM1 | |
| SCHEMBL22075266 | 0.82 | ERCC5 (0.40) | VNN1GRM1KCNQ3KCNQ2KCNQ5 | |
| SCHEMBL22074902 | 0.82 | CES1 (0.54) | VNN1CES2CES1KCNQ3KCNQ2 | |
| SCHEMBL22075124 | 0.81 | PIK3CA (0.40) | FGFR1FGFR4 | |
| SCHEMBL22075351 | 0.81 | CES2 (0.36) | VNN1CES2CES1KCNQ3KCNQ2 | |
| SCHEMBL22074806 | 0.78 | PIK3CA (0.42) | FGFR1FGFR4 | |
| SCHEMBL22103180 | 0.78 | PIK3CA (0.40) | FGFR1FGFR4 | |
| SCHEMBL3158828 | 0.77 | GAA (0.44) | — | |
| SCHEMBL25822604 | 0.74 | GRM4 (0.42) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | VNN1 3395/4885FGFR1 201/4885FGFR4 441/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | VNN1 3395/4885FGFR1 201/4885FGFR4 441/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | VNN1 3395/4885FGFR1 201/4885FGFR4 441/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | VNN1 3395/4885FGFR1 201/4885FGFR4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.